Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.

Viktor Rotbain CurovicNiels JongsMarjolein Y A M KroonenEmilie H ZobelTine W HansenTaha SenGozewijn D LavermanAdriaan KooyFrederik PerssonPeter RossingHiddo J Lambers Heerspink

Published in: Diabetes care (2023)

We demonstrated a large and reproducible variation in participants' responses to different UACR-lowering drug classes. These data support systematic rotation through different drug classes to overcome therapy resistance to RAS inhibition.

Keyphrases

type diabetes
open label
adverse drug
cardiovascular disease
clinical trial
double blind
electronic health record
drug induced
emergency department
phase iii
big data
machine learning
adipose tissue
glycemic control
mesenchymal stem cells
combination therapy